Luitpold Animal Health is committed to the equine industry through sponsorships and partnerships with AQHA.

Luitpold Animal Health, the manufacturer of Adequan® (polysulfated glycosaminoglycan), is dedicated to the joint health of the American Quarter Horse. Luitpold is committed to the equine industry and is made up of people who are passionate about horses and the people who own them. Whether you care for pleasure horses, racehorses, performance horses or working horses, Adequan® may be an asset to your team.

When it comes to Degenerative Joint Disease (DJD), early intervention is key. Catching the signs, diagnosing early and starting treatment can help reverse the degenerative process and help improve joint health.'

Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.2

When you start with it and stay with it, your horse may enjoy greater mobility over a lifetime.1, 3 Ask your veterinarian if Adequan is the right choice for your horse.

Only FDA approved Adequan i.m. has shown to help improve joint function by: 2,4

For more information about Adequan®, joint health, and FDA approval please visit www.adequan.com and www.luitpoldanimalhealth.com.

Adequan® i.m.
Brand of Polysulfated Glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

 

References

1. Mcllwraith C W, Frisbie 00, Kawcak CE, van Weeren PR. Joint Disease in the Horse. St. Louis, MO: Elsevier, 2016; 33-48.
2. Adequan® i.m. (package insert]. Shirley, NY: Luitpold Animal Health; 2008; 2017.
3. Kim DY, Taylor HW, Moore RM, Paulsen OB, Cho DY. Articular chondrocyte apoptosis in equine osteoarthritis. The Veterinary Journal 2003; 166: 52-57.
4. Burba OJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.

Support from AQHA Corporate Partner Adequan helps to fund these events and programs:

Join or Renew Your AQHA Membership